X

Trial Profile

A phase I trial of ABX-101 for Inflammation and Neurodegenerative disorders

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABX 101 Autobahn Therapeutics (Primary)
Indications Inflammation; Neurodegenerative disorders
Focus Adverse reactions

Most Recent Events

24 Jul 2024 According to Autobahn Therapeutics media release, company today announced closing of an oversubscribed $100 million series C financing led by Newpath partners and with the proceeds from this raise, company will advance ABX-101.
18 Sep 2023 New trial record
11 Sep 2023 According to Autobahn Therapeutics media release, company plans to progress the IND enabling study in 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com